# NEO-BLAST: HCP commentary report

> 211 verified statements (63 from clinicians verified by NPI or staff page) from 21 commentary sources · 11 findings · updated Oct 31, 2026

## Report

- Trial: Active Surveillance Versus Definitive Local Therapy for Patients Showing Clinical Complete Response Following Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
- NCT ID: NCT06537154
- Registry: https://clinicaltrials.gov/study/NCT06537154
- Sponsor: Peter Black
- Phase: Phase 2/Phase 3
- Status: Recruiting
- Drugs tested: none (the trial tests no drug)
- Indication: muscle-invasive bladder cancer with clinical complete response
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: 3345fef4380c4eb0f5061805e90e52cf6ddee0518b3192001abd1b4f4e80e767

## Counts

- HCP commentary sources screened: 31
- Sources cited by verified statements: 23
- Verified statements: 211
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 63
- Findings: 11
- Named people in screened sources (unnamed speakers and accounts not counted): 19
- Voices cited: 19
- Cited voices identity-verified: 15

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

NEO-BLAST asks whether localized bladder cancer invading muscle can be managed with surveillance rather than cystectomy or chemoradiation after an apparent complete response to neoadjuvant therapy. Commentary comes from X threads, podcasts and YouTube discussions, including physicians with confirmed oncology roles. The discussion turns on how to assess complete response, whether randomization to surveillance is feasible, and which trade-offs patients might accept if surveillance proves non-inferior.

## Open Medical Affairs question

How should Medical Affairs explain cCR and the systemic-versus-local trade-off without implying that surveillance is established care?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. High response rates are not treated as permission to omit definitive local therapy
- F2. The proposed cCR assessment is composite; no single negative test establishes eligibility
- F3. ctDNA informs systemic-risk selection but does not resolve local disease or surveillance
- F4. Radiotherapy is a connected alternative, but its incremental role after systemic response is disputed
- F5. How should RETAIN and other precursor studies inform local-treatment omission?
- F6. Randomization feasibility, comparator flexibility and physician participation are substantive concerns
- F7. What would non-inferiority permit, and which trade-offs would patients accept?
- F8. Systemic-first reasoning challenges surgery-first practice, with urgent-surgery exceptions
- F9. Regimen preference is qualified by access, platinum alternatives and evidence maturity
- F10. Treatment duration and adjuvant toxicity remain unresolved costs of local de-escalation
- F11. Research proposals diverge on local choice, systemic switching and even systemic omission

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 10 | 17 | 5 | 6 | recorded | 2 |
| F2 | 11 | 6 | 5 | 5 | recorded | 1 |
| F3 | 15 | 7 | 2 | 1 | recorded | 2 |
| F4 | 10 | 13 | 4 | 4 | recorded | 2 |
| F5 | 9 | 6 | 5 | 3 | recorded | 3 |
| F6 | 10 | 6 | 4 | 1 | recorded | 2 |
| F7 | 9 | 6 | 5 | 2 | recorded | 2 |
| F8 | 12 | 15 | 1 | 1 | recorded | 4 |
| F9 | 11 | 16 | 2 | 3 | recorded | 3 |
| F10 | 8 | 6 | 3 | 4 | recorded | 3 |
| F11 | 11 | 11 | 1 | 2 | recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 7 | 0 | 1 | 1 | 1 | 18 | 1 | 2 posts and articles, 3 podcasts and video | yes |
| F2 | 4 | 5 | 0 | 0 | 2 | 11 | 1 | 3 posts and articles, 2 podcasts and video | yes |
| F3 | 12 | 2 | 0 | 1 | 0 | 15 | 1 | 2 podcasts and video | yes |
| F4 | 4 | 4 | 1 | 1 | 0 | 14 | 2 | 3 posts and articles, 1 podcast or video | yes |
| F5 | 8 | 0 | 0 | 0 | 1 | 9 | 0 | 2 posts and articles, 3 podcasts and video | yes |
| F6 | 7 | 2 | 0 | 0 | 1 | 13 | 1 | 3 podcasts and video, 1 publication | yes |
| F7 | 7 | 0 | 1 | 0 | 1 | 10 | 0 | 5 podcasts and video | yes |
| F8 | 5 | 5 | 0 | 1 | 1 | 16 | 3 | 1 podcast or video | yes |
| F9 | 6 | 0 | 1 | 1 | 3 | 15 | 3 | 2 podcasts and video | yes |
| F10 | 3 | 2 | 0 | 0 | 3 | 8 | 0 | 2 posts and articles, 1 podcast or video | yes |
| F11 | 8 | 2 | 1 | 0 | 0 | 11 | 0 | 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Proportion of patients found to have a cCR and randomized on the number of patients enrolled (pilot-RCT ; phase 2): F6 (6 shared claims), F9 (1 shared claims)
- Primary endpoint: Metastasis free survival at 2 years (phase 3): F1 (1 shared claims), F6 (1 shared claims), F7 (3 shared claims)
- Secondary endpoints: F1 (1 shared claims), F2 (1 shared claims), F6 (1 shared claims), F7 (4 shared claims)
- Population and setting: F3 (4 shared claims), F7 (2 shared claims), F8 (4 shared claims), F9 (4 shared claims)
- The comparison: F1 (6 shared claims), F4 (9 shared claims), F5 (1 shared claims), F6 (1 shared claims)
- Safety and tolerability: F2 (1 shared claims), F3 (1 shared claims), F4 (1 shared claims), F5 (2 shared claims), F7 (5 shared claims), F8 (1 shared claims), F10 (5 shared claims)
- Design and conduct: F5 (3 shared claims), F6 (9 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. The proposed cCR assessment is composite; no single negative test establishes eligibility

On YouTube, a speaker described in the source as involved in NEO-BLAST asks how complete response can be identified reliably and whether bladder treatment remains necessary for those patients.

Source: YouTube video, 2025-02-17.

### F6. Randomization feasibility, comparator flexibility and physician participation are substantive concerns

On YouTube, a speaker described in the source as involved in NEO-BLAST asks whether patients would accept random assignment to surveillance or definitive bladder treatment and continue their allocated care. The interview also asks whether physicians would refer patients and continue treating them within the study.

Source: YouTube video, 2026-10-08.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 11 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 211 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 23 | Counts free |
| Speaker attribution for cited voices | 19 | Paid |

## Trial aspects

12 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Proportion of patients found to have a cCR and randomized on the number of patients enrolled (pilot-RCT ; phase 2) | discussed | 9 | 3 |
| Primary endpoint: Metastasis free survival at 2 years (phase 3) | discussed | 7 | 4 |
| Secondary endpoints | discussed | 10 | 5 |
| Population and setting | discussed | 19 | 6 |
| The comparison | discussed | 29 | 9 |
| Safety and tolerability | discussed | 20 | 7 |
| Design and conduct | discussed | 19 | 5 |
| Clinical complete response, biomarker interpretation and local versus systemic risk | discussed | 46 | 8 |
| Antecedent evidence and the threshold for changing practice | discussed | 29 | 13 |
| Upfront systemic choice, access, sequencing and referral | discussed | 42 | 4 |
| Systemic exposure, adjuvant necessity and alternative research strategies | discussed | 39 | 4 |
| Patient-valued non-inferiority, surveillance burden and decision support | discussed | 20 | 7 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 23 | 13 |
| YouTube | 4 | 4 |
| Podcasts | 3 | 3 |
| X videos | 1 | 1 |
| Publications (primary source, cited for context) | not screened | 1 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2025-02-17 to 2026-10-31
- Cited window: 2025-02-17 to 2026-10-31
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Active Surveillance Versus Definitive Local Therapy for Patients Showing Clinical Complete Response Following Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
- Registry: NCT06537154 (https://clinicaltrials.gov/study/NCT06537154)
- Study IDs: H23-02447
- Sponsor: Peter Black
- Collaborators: University of British Columbia, Canadian Institutes of Health Research (CIHR)
- Design: Phase 2/Phase 3 · interventional, randomized, parallel, phase2, phase3
- Status: Recruiting
- Enrollment: 688 (estimated)
- Start: 2025-07-28 (actual)
- Primary completion: 2028-12-31 (estimated)
- Primary endpoint: Proportion of patients found to have a cCR and randomized on the number of patients enrolled (pilot-RCT ; phase 2) (24 months)
- Primary endpoint: Metastasis free survival at 2 years (phase 3) (24 months)
- Intervention: Active Surveillance (procedure)
- Intervention: Control arm - Definitive bladder treatment (procedure)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on cystectomy standards and neoadjuvant systemic therapy informing bladder-preservation decisions in muscle-invasive bladder cancer.
- Not yet captured in this edition: a view on rigorous complete-response assessment, consistent definitions, and further evidence needed for response-guided bladder preservation.
- Not yet captured in this edition: a view on neoadjuvant treatment amendments and adjuvant treatment switching in muscle-invasive bladder cancer.
- Not yet captured in this edition: a question about early stopping and interpretation of the available neoadjuvant evidence.
- Not yet captured in this edition: a view on pragmatic adaptation of neoadjuvant treatment studies and trade-offs between timely access and treatment heterogeneity.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 73 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits apply, so some matching discussion may be missing.
- The sources describe planned NEO-BLAST methods and conditional future implications, not comparative evidence establishing surveillance as non-inferior.
- Some portions of reviewed recordings and threads were not fully assessed for relevant views. The report therefore cannot claim exhaustive coverage despite including substantial connected discussion.
- Missing connected material includes contrasting disappointment about an unpresented pembrolizumab arm, reasoning about limited expected incremental neoadjuvant benefit from single-agent checkpoint treatment, experience with Ambassador and speculation about immature data. These absences limit interpretation of the available systemic-treatment evidence.
- Other missing discussion concerns uncertainty about whether another arm had reported, a question about early stopping, and praise for adapting an existing study to include EV–pembrolizumab with faster access, time saved and acknowledged heterogeneity. Another relevant missing view lacks enough detail to characterize.
- The separate discussion of whether treatment was standard throughout the perioperative study, including at its start, and the objection to changing a comparator mid-study is not represented. The account of contemporary surgery-control patients must not be read as a complete assessment of comparator selection.
- Coverage is also incomplete for a speaker's connected discussion of MODERN amendments and adjuvant treatment changes, including LAG-3 treatment with relatlimab and its melanoma-approval context. Some linked discussion of systemic-treatment efficacy, cystectomy's standard role, rigorous and uniform cCR assessment, consistent definitions and the need for further study is absent. These gaps limit the completeness of the treatment-switch and response-selection themes.
- Some speech cannot be assigned to a named participant. It is attributed only to the recording and must not be counted as an additional independent clinician or assumed to contradict a named participant in that recording.
- Relayed presentation or podcast views remain the original party's reported views, not the relayer's endorsement. Reposts and parallel-language summaries do not establish independent agreement.
- Several clinical roles are not independently established in the sources reviewed. Source-described roles or trial involvement are identified as such; identity information does not establish who spoke otherwise unattributed words.
- Precursor-study figures are speakers' reports or interpretations, sometimes approximate or uncertain. They are not NEO-BLAST outcomes and do not establish causation, cross-study equivalence or validated selection rules.
- Descriptions of the pilot's 25% threshold differ in their denominator wording. A speaker and the registry describe the joint cCR-and-randomization proportion among enrolled patients; the protocol abstract phrases acceptance among patients with cCR.
- The precise Health Canada approval timing for EV–pembrolizumab remains unclear, and easier attainment of the feasibility target is a speaker's expectation rather than a reported feasibility result. The passage describing the 10% non-inferiority margin does not specify its endpoint or timepoint.
- No separate protocol file was available from the registry. The registry methods and protocol publication provide context, not a complete assessment of every operational or safety question.
- Source dates are publication or post dates unless an event is explicitly named. They cannot establish a readout date, a session date or a change in a person's position.
- The report describes this edition's reviewed discussion, not the prevalence of views among HCPs or all public commentary.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition

Last checked for new commentary 2026-10-31. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Standard (211 verified statements)
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $2,200
- 6 months of weekly updates: $3,100
- 12 months of weekly updates: $4,400
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (15 now), at most $1,250; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/neo-blast-nct06537154
- Agents: POST https://www.erudio.com/api/orders with {"report": "neo-blast-nct06537154", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=neo-blast-06537154

## Cite

Erudio Health. NEO-BLAST (NCT06537154): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/neo-blast-nct06537154

## Machine access

- JSON: https://www.erudio.com/reports/neo-blast-nct06537154.json
- Markdown: https://www.erudio.com/reports/neo-blast-nct06537154.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "neo-blast-06537154"}`